Determination of tenatoprazole enantiomers and their enantioselective pharmacokinetics in rats

Chirality

Volumn 21, Issue 6, 2009, Pages 613-618

  Guan, Jin ^a,b   Yang, Jing ^a   Li, Jingjing ^a   Li, Xiaohong ^a   Li, Famei ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHENYANG UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

Chiral stationary phase; Enantioselectivity; Enantioseparation; HPLC; Pharmacokinetic parameter; Proton pump inhibitor; Rat plasma

Indexed keywords

2 PROPANOL; BENATOPRAZOLE; DICHLOROMETHANE; HEXANE; OMEPRAZOLE; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHIRAL CHROMATOGRAPHY; CHIRALITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; ENANTIOMER; ENANTIOSELECTIVITY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT; ANIMAL; BLOOD; CHEMISTRY; ENZYME SPECIFICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ORAL DRUG ADMINISTRATION; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STEREOISOMERISM; TIME; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; IMIDAZOLES; LINEAR MODELS; MALE; OMEPRAZOLE; RATS; RATS, WISTAR; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 67649415480     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20657     Document Type: Article

References (17)

1. Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract 2005;59:709-715.
2. Shina JM, Homerin M, Domagala F, Ficheux H, Sachs G. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+-ATPase in vitro and in vivo. Biochem Pharmacol 2006;71:837-849.
3. Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y. The long-lasting effect of TU-199, a novel H+, K+-ATPase inhibitor, on gastric acid secretion in dogs. J Pharmacy Pharmcol 1999;51:457-464.
4. Kananzawa H, Okada A, Higaki M, Yokota H, Mashige F, Nakahara K. Stereospecific analysis of omeprazole in human plasma as a probe for CYP2C19 phenotype. J Pharm Biomed Anal 2003;30:1817-1824.
5. Tybring G, Bottiger Y, Widen J, Bertillsson L. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 1997;62:129-137.
6. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001;40:411-426.
7. Liu P, Sun B, Lu X, Qin F, Li F. HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule. Biomed Chromatogr 2007;21:89-93.
8. Satio S, Sebata N, Ishiwata T, Kinbara M, Morotome K. Pharmacokinetic studies of (±)-5-Methoxy-2- (4-methoxy-3,5-dimethylpyrid-2-yl) methyl]sulfinyl]-1H-imidazo[4,5-b]pyridine (TU-199). Iyakuhin Kenkyu 1999;30:119-127.
9. Nirogi R, Kandikere V, Mudigonda K, Bhyrapuneni G. Quantification of tenatoprazole in rat plasma by HPLC: validation and its application to pharmacokinetic studies. Biomed Chromatogr 2007;21:1240-1244.
10. Domagala F, Ficheux H, Houin G, Barre J. Pharmacokinetics of tenatoprazole, a newly synthesized proto pump inhibitor, in healthy male Caucasian volunteers. Arzneimittel Forschung 2006;56:33-39.
11. Lu X, Liu P, Chen H, Qin F, Li F. Enantioselective pharmcokinetics of mabuterol in rats studied using sequential achiral and chiral HPLC. Biomed Chromatogr 2005;19:703-708.
12. Xie Z, Zhang Y, Xu H, Zhong D. Pharmacokinetic differences between Pantoprazole enantiomers in rats. Pharm Res 2005;22:1678-1684.
13. USFDA. 2001: http:www.fda.gov/guidance/4252 fnl.htm.
14. Abelo A, Andersson TB, Antosson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Durg Metab Dispos 2000;28:966-972.
15. Arimori K, Yasuda K, Katsuki H, Nakano M. Pharmacokinetic differences between lansoprazole enantiomers in rats. J Pharm Pharmacol 1998;50:1241-1245.
16. Kim KA, Kim MJ, Park JY, Shon JH, Yoon YR, Lee SS, Liu MH, Shin JG. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Durg Metab Dispos 2003;31:1227-1234.
17. Miura M, Kagaya H, Tada H, Uno T, Yasui-Furukori N, Tateishi T, Suzuki T. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. Br J Clin Pharmacol 2006;61:315-320.